Skip to main content

BMRN

Stock
Health Care
Biotechnology

Performance overview

BMRN Price
Price Chart

Forward-looking statistics

Beta
0.61
Risk
31.40%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

BioMarin's focus is on rare-disease therapies. Genzyme markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.

Company info

SectorHealth Care
IndustryBiotechnology
Employees4K
Market cap$15.3B

Fundamentals

Enterprise value$9.9B
Revenue$3.0B
Revenue per employee—
Profit margin17.76%
Debt to equity10.39

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.70
Dividend per share—
Revenue per share$15.48
Avg trading volume (30 day)$135M
Avg trading volume (10 day)$140M
Put-call ratio—

Macro factor sensitivity

Growth-0.1
Credit+3.7
Liquidity+0.8
Inflation-3.0
Commodities-0.9
Interest Rates-1.2

Valuation

Dividend yield0.00%
PEG Ratio19.23
Price to sales3.74
P/E Ratio19.23
Enterprise Value to Revenue3.35
Price to book1.90

Upcoming events

Next earnings dayAugust 4, 2025
Next dividend day—
Ex. dividend day—

News

Here's Why BioMarin Pharmaceutical (BMRN) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Zacks Investment Research (July 11, 2025)
It is time for a move higher in biotech, says Mizuho's Jared Holz

Jared Holz, Mizuho, joins 'Closing Bell Overtime' to discuss if the biotech sector is ready for a breakout.

CNBC Television (July 7, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free